Physical and hormonal evaluation of transsexual patients during hormonal therapy

• Published in: Archives of sexual behavior 1981-08, Vol.10 (4), p.347-356
• Main Authors: Meyer, 3rd, W J, Finkelstein, J W, Stuart, C A, Webb, A, Smith, E R, Payer, A F, Walker, P A
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Estrogens - blood; Estrogens - therapeutic use; Ethinyl Estradiol - therapeutic use; Female; Follicle Stimulating Hormone - blood; Gonadal Steroid Hormones - therapeutic use; Humans; Luteinizing Hormone - blood; Male; Middle Aged; Physical Examination; Testosterone - analogs & derivatives; Testosterone - blood; Testosterone - therapeutic use; Transsexualism - drug therapy
• ISSN: 0004-0002; 1573-2800
• DOI: 10.1007/BF01565538

The optimal hormonal therapy for transsexual patients is not known. The physical and hormonal characteristics of 38 noncastrate male-to-female transsexuals and 14 noncastrate female-to-male transsexuals have been measured before and/or during therapy with various forms and dosages of hormonal therapy. All patients were hormonally and physically normal prior to therapy. Ethinyl estradiol was superior to conjugated estrogen in suppression of testosterone and gonadotropins but equal in effecting breast growth. The changes in physical and hormonal characteristics were the same for 0.1 mg/d and 0.5 mg/d of ethinyl estradiol. The female-to-male transsexuals were well managed with a dose of intramuscular testosterone cypionate of 400 mg/month, usually given 200 mg every two weeks. The maximal clitoral length reached was usually 4 cm. Higher doses of testosterone did not further increase clitoral length or suppression of gonadotropins; lower doses did not suppress the gonadotropins. Based on the information found in this study, we recommend 0.1 mg/d of ethinyl estradiol for the noncastrate male-to-female transsexual and 200 mg of intramuscular testosterone cypionate every two weeks for the noncastrate female-to-male transsexual.